IGF-1 LR3

Also known as: Long R3 IGF-1, LR3 IGF-I

Evidence Tier Cextreme riskadvancednot approved

Engineered IGF-1 analogue with reduced IGFBP binding and prolonged activity. Extreme growth-factor risk category.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Extreme Risk

This substance is in the extreme platform risk category due to growth-factor signaling, mitogenic potential, or complete absence of human safety data. Exercise maximum caution.

Mitogenic Risk

This substance has mitogenic (cell-proliferation-promoting) properties. Growth-factor class risks include hypoglycemia and potential promotion of abnormal cell growth.

Overview

IGF-1 LR3 (Long R3 IGF-1) is an engineered IGF-1 analogue with reduced binding to IGF binding proteins and prolonged activity versus native IGF-1. Animal research shows superior potency to injected IGF-1. Growth-factor class risks include hypoglycemia and mitogenic signaling. WADA lists IGF-1 and analogues under S2. This is an extreme compliance risk item for any consumer-facing platform.

Research Details

Mechanism of Action

IGF-1 receptor agonism with altered binding protein interactions; prolonged activity vs native IGF-1.

Study Dose Range

Animal research: injection/infusion comparisons. No established human consumer dosing.

Administration Routes

subcutaneous

Onset / Timeline

Acute metabolic effects possible; anabolic narratives are speculative in consumer context.

Expected Effects

Growth factor signaling; muscle growth narratives in gray market. High mitogenic/glucose risk.

Adverse Effects

Hypoglycemia, mitogenic signaling, growth-factor class risks.

Contraindications

Active malignancy (by analogy to growth factor class). High interaction potential with insulin/glucose-lowering agents.

Interaction Notes

High interaction potential with insulin/glucose-lowering agents; avoid prescriptive guidance.

Related Goals

Muscle Growth & Strength

Known Interactions

caution with Tesamorelin

Tesamorelin increases IGF-1 (label); combining with IGF-axis agonists increases proliferative/hypoglycemia monitoring complexity.

contraindicated with PEG-MGF

High-risk IGF/MGF clustering; insufficient safety basis for consumer routing; FDA flags PEG-MGF compounding risks and no identified human exposure data.

contraindicated with Follistatin

Growth-factor cluster; strong clinical-only gating recommended.

caution with FOXO4-DRI

FOXO4-DRI is a senolytic research peptide with limited human data; avoid combining with high-mitogenic axis in consumer protocols.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

GHRP-6

GH secretagogue with phase I PK data in humans. FDA has flagged compounding safety concerns.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.